Adalimumab levels detected in cord blood and infants exposed in utero
Adalimumab (ADA), a drug often prescribed for women with Crohn's disease, actively crosses the placenta during the final trimester of pregnancy and remains in a newborn's bloodstream for at least three...
View ArticleTargeted adalimumab treatment can optimize long-term outcomes for patients...
Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease...
View ArticleBiological agents for rheumatoid arthritis associated with increased skin...
Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic...
View ArticleUVB preferred for treatment of moderate to severe psoriasis
(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in...
View ArticleTreating psoriasis to prevent heart attacks and strokes
A clinical study co-led by the Montreal Heart Institute and Innovaderm Research Inc., which was presented today at the annual meeting of the American Academy of Dermatology, shows that a new treatment...
View ArticleStudy compares effectiveness of psoriasis treatments
(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the...
View ArticleTocilizumab is more effective than adalimumab at reducing signs and symptoms...
Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the...
View ArticleTreatment with anti-TNFs can increase the risk of shingles by up to 75 percent
Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients...
View ArticleHead-to-head study in RA shows that abatacept has comparable efficacy to...
Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year,...
View ArticleHep B screening urged before TNF-alpha inhibitor therapy
(HealthDay) -- All patients with psoriasis should be screened for hepatitis B surface antigen and hepatitis B core antibody prior to the initiation of tumor necrosis factor-alpha inhibitor therapy,...
View ArticleAdalimumab is a promising therapy for children with Crohn's disease
Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the...
View ArticleNo difference in death rates among patients exposed to common rheumatoid...
New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab...
View ArticleStudy shows efficacy of new rheumatoid arthritis drug
(Medical Xpress) -- A new study involving researchers from Karolinska Institutet demonstrates the efficacy of Tofacitinib, a new drug for rheumatoid arthritis. According to the study, which is...
View ArticleUsing antibodies against immune deficiency
Early, intensive therapy with a biotechnologically produced medication can provide significantly faster pain relief for patients with rheumatic joint inflammation. Damage to joints can also be reduced...
View ArticleHumira's approval widened to include ulcerative colitis
(HealthDay)—Humira (adalimumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe ulcerative colitis in adults, the agency said Friday.
View ArticleImmunogenicity strongly impacts response to adalimumab in RA
(HealthDay)—For patients with rheumatoid arthritis (RA), long-term clinical outcomes are good with etanercept and adalimumab; but for adalimumab, treatment response is strongly dependent on the...
View ArticleAdalimumab relieves hidradenitis suppurativa
(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin,...
View ArticleDoctors' perceptions of psoriasis therapies vary
(HealthDay)—Doctors who treat patients with psoriasis show wide variation in their beliefs about the safety and effectiveness of psoriasis treatments, according to a study published in the February...
View ArticlePatient expresses concern about lack of data on biological drugs
(HealthDay)—A patient with Crohn's disease is concerned about the attempt by the makers of adalimumab to prevent disclosure of trial data submitted during the drug's approval process, according to a...
View ArticleFrequently used biologic agents might cause acute liver injury
A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official...
View Article
